Exosens
EXENS.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.50 | 0.69 | -0.50 | -0.00 |
| FCF Yield | 9.75% | 3.21% | 4.23% | 3.80% |
| EV / EBITDA | 9.82 | 10.77 | 16.28 | -7.91 |
| Quality | ||||
| ROIC | 7.90% | 9.03% | 4.28% | 7.69% |
| Gross Margin | 57.24% | 55.46% | 56.76% | 60.20% |
| Cash Conversion Ratio | 3.13 | 2.74 | 4.24 | -0.29 |
| Growth | ||||
| Revenue 3-Year CAGR | 25.21% | 24.26% | 10.24% | 5,497,618.06% |
| Free Cash Flow Growth | 392.68% | -23.98% | 11.35% | -24.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.25 | 3.53 | 4.42 | -1.90 |
| Interest Coverage | 2.76 | 1.80 | 2.01 | 0.85 |
| Efficiency | ||||
| Inventory Turnover | 1.81 | 1.81 | 1.56 | 1.47 |
| Cash Conversion Cycle | 210.89 | 198.08 | 197.22 | 238.92 |